The US Food and Drug Administration (FDA) has approved brexanolone intravenous infusion (Zulresso, Sage Therapeutics), the first-ever drug indicated for the treatment of postpartum depression. The drug is administered under medical supervision as a continuous infusion over a total of 60 hours (2.5 days), according to the FDA. Postpartum depression can [...]
On individuals with major depressive disorder (MDD), particularly those who experience suicidal thinking, levels of translocator protein (TSPO), a marker of microglial inflammation, are increased, new research shows. Investigators from the University of Manchester, United Kingdom, found significantly higher levels of TSPO in patients with MDD than in healthy control [...]
The US Food and Drug Administration (FDA) has approved a new formulation of methylphenidate for children with attention-deficit/hyperactivity disorder (ADHD). Cotempla XR-ODT (Neos Therapeutics Inc) is the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of ADHD in patients aged 6 to 17 years, the company said [...]
By Megan Brooks BOSTON — Sleep-disordered breathing (SDB) may play a role in persistent depressive symptoms and poor response to standard pharmacologic treatments in adolescents, new research suggests. Screening adolescents with treatment-resistant depression (TRD) for SBD "may be clinically valuable, since SDB is readily treatable," said Teena Chase, MD, PhD, Department [...]
By Nassir Ghaem Wide-Ranging Benefits At the recent American Psychiatric Association annual meeting in San Diego, an update symposium was presented on the topic of "Lithium: Key Issues for Practice."[1] In a session chaired by Dr David Osser, associate professor of psychiatry at Harvard Medical School, presenters reviewed various aspects of [...]
MIAMI – Medications in development for the treatment of attention-deficit/hyperactivity disorder (ADHD) target specific behaviors, such as impulsive aggression, and genes that involve the glutamatergic network, new research shows. In the first of two studies presented here at the American Society of Clinical Pharmacology (ASCP), researchers reported on improvements in [...]
New Insight Into Off-Label Ketamine Use for Depression By Nancy A. Melville MIAMI – As the off-label use of ketamine for the treatment of severe depression continues to soar, two new studies provide insight into the way clinicians are using it in the field, away from the research setting. In [...]
Treatment with the diuretic bumetanide (Bumex, Validus) improved core symptoms of autism spectrum disorder (ASD), including social deficits and stereotyped behaviors, results from a multicenter phase 2b study show. Bumetanide was effective in improving ASD-related symptoms across the pediatric age range, as assessed by the Childhood Autism Rating Scale (CARS), [...]
What Will Health Care Look like in 20-Years? The Microbiome: Beyond the Gut The Microbiome/Inflammation/Infection Link The Microbiome/Environment Link Genomics: The Revolution We've All Been Waiting For Pharmacogenomics Medicine Goes Mobile Immunotherapy ... and more Courtesy Medscape The Microbiome: Beyond the Gut Understanding of the world beneath—the seething, teeming microbial [...]